Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
AstraZeneca
McKesson
Moodys
Mallinckrodt

Last Updated: May 27, 2022

VELPHORO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Velphoro patents expire, and what generic alternatives are available?

Velphoro is a drug marketed by Vifor Fresenius and is included in one NDA. There are ten patents protecting this drug.

This drug has ninety-nine patent family members in thirty-four countries.

The generic ingredient in VELPHORO is ferric oxyhydroxide. There are twenty drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the ferric oxyhydroxide profile page.

DrugPatentWatch® Generic Entry Outlook for Velphoro

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 23, 2030. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Drug patent expirations by year for VELPHORO
Drug Prices for VELPHORO

See drug prices for VELPHORO

DrugPatentWatch® Estimated Generic Entry Opportunity Date for VELPHORO
Generic Entry Date for VELPHORO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET, CHEWABLE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VELPHORO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Colorado, DenverPhase 4
Vifor Fresenius Medical Care Renal PharmaPhase 2
Prim. Priv. Doz. Dr. Daniel CejkaPhase 2

See all VELPHORO clinical trials

US Patents and Regulatory Information for VELPHORO

VELPHORO is protected by ten US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VELPHORO is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VELPHORO

Pharmaceutical composition, comprising phosphate binder particles
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Pharmaceutical compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Pharmaceutical compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Pharmaceutical compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Pharmaceutical compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Pharmaceutical compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Pharmaceutical compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Pharmaceutical compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Pharmaceutical composition, comprising phosphate binder particles
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Pharmaceutical compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vifor Fresenius VELPHORO ferric oxyhydroxide TABLET, CHEWABLE;ORAL 205109-001 Nov 27, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Vifor Fresenius VELPHORO ferric oxyhydroxide TABLET, CHEWABLE;ORAL 205109-001 Nov 27, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Vifor Fresenius VELPHORO ferric oxyhydroxide TABLET, CHEWABLE;ORAL 205109-001 Nov 27, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Vifor Fresenius VELPHORO ferric oxyhydroxide TABLET, CHEWABLE;ORAL 205109-001 Nov 27, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for VELPHORO

When does loss-of-exclusivity occur for VELPHORO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 9312
Estimated Expiration: See Plans and Pricing

Australia

Patent: 08322963
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 0820308
Estimated Expiration: See Plans and Pricing

Canada

Patent: 00444
Estimated Expiration: See Plans and Pricing

China

Patent: 1861146
Estimated Expiration: See Plans and Pricing

Patent: 4688702
Estimated Expiration: See Plans and Pricing

Patent: 6619710
Estimated Expiration: See Plans and Pricing

Patent: 1789820
Estimated Expiration: See Plans and Pricing

Patent: 2022796
Estimated Expiration: See Plans and Pricing

Patent: 2022821
Estimated Expiration: See Plans and Pricing

Patent: 2022822
Estimated Expiration: See Plans and Pricing

Colombia

Patent: 80398
Estimated Expiration: See Plans and Pricing

Croatia

Patent: 0170034
Estimated Expiration: See Plans and Pricing

Patent: 0181837
Estimated Expiration: See Plans and Pricing

Cyprus

Patent: 18496
Estimated Expiration: See Plans and Pricing

Patent: 21230
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 22285
Estimated Expiration: See Plans and Pricing

Patent: 43992
Estimated Expiration: See Plans and Pricing

Patent: 92069
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 22285
Estimated Expiration: See Plans and Pricing

Patent: 43992
Estimated Expiration: See Plans and Pricing

Patent: 92069
Estimated Expiration: See Plans and Pricing

Patent: 95698
Estimated Expiration: See Plans and Pricing

Patent: 95699
Estimated Expiration: See Plans and Pricing

Patent: 95700
Estimated Expiration: See Plans and Pricing

Guatemala

Patent: 1000144
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 07298
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 31293
Estimated Expiration: See Plans and Pricing

Patent: 41429
Estimated Expiration: See Plans and Pricing

Israel

Patent: 5726
Estimated Expiration: See Plans and Pricing

Patent: 7741
Estimated Expiration: See Plans and Pricing

Japan

Patent: 66164
Estimated Expiration: See Plans and Pricing

Patent: 61601
Estimated Expiration: See Plans and Pricing

Patent: 94260
Estimated Expiration: See Plans and Pricing

Patent: 38734
Estimated Expiration: See Plans and Pricing

Patent: 64959
Estimated Expiration: See Plans and Pricing

Patent: 11503148
Estimated Expiration: See Plans and Pricing

Patent: 14062120
Estimated Expiration: See Plans and Pricing

Patent: 15166359
Estimated Expiration: See Plans and Pricing

Patent: 17114873
Estimated Expiration: See Plans and Pricing

Patent: 19089805
Estimated Expiration: See Plans and Pricing

Patent: 21001192
Estimated Expiration: See Plans and Pricing

Lithuania

Patent: 22285
Estimated Expiration: See Plans and Pricing

Patent: 43992
Estimated Expiration: See Plans and Pricing

Malaysia

Patent: 6383
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 10005346
Estimated Expiration: See Plans and Pricing

Morocco

Patent: 898
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 5435
Estimated Expiration: See Plans and Pricing

Philippines

Patent: 015500727
Estimated Expiration: See Plans and Pricing

Poland

Patent: 22285
Estimated Expiration: See Plans and Pricing

Patent: 43992
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 22285
Estimated Expiration: See Plans and Pricing

Patent: 43992
Estimated Expiration: See Plans and Pricing

Russian Federation

Patent: 93831
Estimated Expiration: See Plans and Pricing

Patent: 48760
Estimated Expiration: See Plans and Pricing

Patent: 10124424
Estimated Expiration: See Plans and Pricing

Patent: 13128356
Estimated Expiration: See Plans and Pricing

Saudi Arabia

Patent: 2340044
Estimated Expiration: See Plans and Pricing

Singapore

Patent: 8789
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 22285
Estimated Expiration: See Plans and Pricing

Patent: 43992
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 1004256
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1438071
Estimated Expiration: See Plans and Pricing

Patent: 1590115
Estimated Expiration: See Plans and Pricing

Patent: 100126266
Estimated Expiration: See Plans and Pricing

Patent: 130030306
Estimated Expiration: See Plans and Pricing

Spain

Patent: 12331
Estimated Expiration: See Plans and Pricing

Patent: 03158
Estimated Expiration: See Plans and Pricing

Taiwan

Patent: 68167
Estimated Expiration: See Plans and Pricing

Patent: 92159
Estimated Expiration: See Plans and Pricing

Patent: 0938210
Estimated Expiration: See Plans and Pricing

Patent: 1509423
Estimated Expiration: See Plans and Pricing

Tunisia

Patent: 10000152
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VELPHORO around the world.

Country Patent Number Title Estimated Expiration
Mexico 2016006916 COMPOSICION FARMACEUTICA, QUE COMPRENDE PARTICULAS DE AGLUTINANTE DE FOSFATO. (PHARMACEUTICAL COMPOSITION, COMPRISING PHOSPHATE BINDER PARTICLES.) See Plans and Pricing
Canada 2240668 ADSORBANTS POUR PHOSPHATES FORMES A PARTIR D'AGENTS AQUEUX, LEUR PRODUCTION ET LEUR UTILISATION (ADSORBENT FOR PHOSPHATE FROM AN AQUEOUS MEDIUM, PRODUCTION AND USE OF SAID ADSORBENT THEREOF) See Plans and Pricing
Hong Kong 1207298 藥物組合物 (PHARMACEUTICAL COMPOSITIONS) See Plans and Pricing
Brazil PI0820308 Composições farmacêuticas See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VELPHORO

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0868125 CA 2015 00007 Denmark See Plans and Pricing PRODUCT NAME: BLANDING AF POLYNUKLEAERT JERN(III)-OXYHYDROXID, SUCROSE OG STIVELSE; REG. NO/DATE: EU/1/14/943/001-004 20140826
0868125 SPC/GB14/087 United Kingdom See Plans and Pricing PRODUCT NAME: MIXTURE OF POLYNUCLEAR IRON(III)OXYHYDROXIDE, SUCROSE AND STARCHES; REGISTERED: UK EU/1/14/943/001 20140828; UK EU/1/14/943/002 20140828; UK EU/1/14/943/003 20140828; UK EU/1/14/943/004 20140828
0868125 PA2015003 Lithuania See Plans and Pricing PRODUCT NAME: POLICIKLINES GELEZIES (III) OKSIHIDROKSIDO, SACHAROZES IR KRAKMOLU MISINYS; REGISTRATION NO/DATE: EU/1/14/943/001 - EU/1/14/943/004 20140826
0868125 C00868125/01 Switzerland See Plans and Pricing PRODUCT NAME: FERRIOXYHYDROXIDUM/SACCHARUM/AMYLA; REGISTRATION NO/DATE: SWISSMEDIC 62986 22.01.2015
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Harvard Business School
Express Scripts
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.